Viridian Therapeutics (NASDAQ:VRDN) Posts Quarterly Earnings Results, Beats Estimates By $0.21 EPS

Viridian Therapeutics (NASDAQ:VRDN) announced its earnings results on Wednesday. The company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($1.02) by $0.21, FiscalAI reports. The firm had revenue of $25.75 million during the quarter, compared to the consensus estimate of $4.72 million. Viridian Therapeutics had a negative return on equity of 72.97% and a negative net margin of 505.86%.

Here are the key takeaways from Viridian Therapeutics’ conference call:

• LUMVOA generated $24.7 million in net product revenue in its first launch quarter, with more than 100 patients having started treatment by September 30. Management said the revenue was demand-driven, not primarily inventory stocking.
• The company reported payer policies covering 30% of covered lives by quarter-end, with parity access in almost all cases, and said it remains on track for broad coverage six to nine months after launch. CMS assigned LUMVOA a permanent J-code effective January 1, 2027.
• Management called the launch encouraging but emphasized it is still early and said uptake will need to be assessed over subsequent quarters; it declined to provide Q4 guidance or quantify market share.
• Viridian said it remains on track to submit elegrobart’s BLA in Q1 2027, expects to begin a Phase I trial of VRDN-292 in Graves’ disease later this quarter, and plans to share first-in-human data for VRDN-008 later this quarter.
• The company ended the quarter with just over $955 million in cash, cash equivalents, and marketable securities, which management said is sufficient to fund current business plans through profitability.

Viridian Therapeutics Stock Up 15.5%

NASDAQ VRDN opened at $29.06 on Thursday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 16.95 and a current ratio of 16.95. The firm has a 50-day simple moving average of $21.80 and a 200 day simple moving average of $21.85. Viridian Therapeutics has a twelve month low of $13.18 and a twelve month high of $34.29. The stock has a market cap of $3.29 billion, a PE ratio of -8.62 and a beta of 1.07.

Key Viridian Therapeutics News

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: Viridian reported a Q3 loss of $0.81 per share, narrower than analysts’ expected loss of $1.01–$1.02. Revenue of $25.75 million also exceeded the roughly $4.72 million consensus estimate. The EPS loss was nevertheless wider than the $0.34 loss a year earlier. Viridian Q3 results
• Positive Sentiment: Management signaled it is targeting a biologics license application for elegrobart in Q1 2027 and expects Lumvoa’s launch to reach broad coverage within six to nine months—milestones that could strengthen the commercial and pipeline outlook. Elegrobart and Lumvoa outlook
• Positive Sentiment: Needham raised its price target to $38 from $34 and maintained a Buy rating, reflecting a more optimistic analyst view of VRDN’s prospects. Needham price target update
• Negative Sentiment: A Yahoo Finance commentary said VRDN looks overvalued even with its new launch, highlighting valuation as a potential concern after the stock’s strong performance. Valuation commentary

Insiders Place Their Bets

In related news, insider Jennifer Tousignant sold 14,212 shares of Viridian Therapeutics stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $24.50, for a total transaction of $348,194.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 2.40% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research analysts have commented on the company. Royal Bank Of Canada lifted their price target on Viridian Therapeutics from $36.00 to $38.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 22nd. Truist Financial increased their price objective on Viridian Therapeutics from $38.00 to $39.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Wall Street Zen downgraded shares of Viridian Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Sunday, October 4th. Needham & Company LLC raised their price objective on shares of Viridian Therapeutics from $34.00 to $38.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, Weiss Ratings raised shares of Viridian Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, September 14th. Ten equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $37.45.

About Viridian Therapeutics

Viridian Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for serious autoimmune diseases. The company’s lead research area is thyroid eye disease (TED), a debilitating condition that can cause eye inflammation, swelling, pain and vision-related complications.

Viridian’s pipeline is centered on antibodies designed to inhibit the insulin-like growth factor-1 receptor (IGF-1R), a target associated with TED. Its investigational therapies include veligrotug (VRDN-001), an intravenous treatment candidate, and VRDN-003, a subcutaneous formulation being developed to provide a more convenient administration option.